广济药业公告，预计2025年度归母净利润亏损5.18亿元至3.99亿元，上年同期为亏损2.95亿元。报告期 内，受行业市场竞争持续加剧影响，公司主要产品销售价格长期处于低位，未能呈现回暖态势。在此背 景下，公司产能利用率及整体经营业绩均未达预期，导致公司报告期内仍处于经营性亏损状态。 ...

Core Viewpoint - The company,拓新药业, is forecasting a significant increase in losses for the fiscal year 2025, projecting a loss between 54 million to 73 million yuan, which is a substantial increase compared to the previous year's loss of approximately 19.88 million yuan [1]. Financial Performance - For the first three quarters of 2025, the company's operating revenue decreased by 16.64%, with a net loss of approximately 30.16 million yuan, indicating that the fourth quarter of the previous year alone saw losses exceeding the total losses of the first three quarters [1]. - The company has reported consecutive annual losses for two years, with the loss margin increasing significantly [1]. Management Response - In response to the ongoing losses, the company is actively implementing multiple measures aimed at improving operational performance and achieving profitability [1][2]. - The company acknowledges that the decline in overall business performance is primarily due to fluctuations in demand and declining market prices for certain raw material products, which have adversely affected sales revenue and gross margins [2]. - The company is also facing high fixed costs due to the gradual release of new production capacity from completed investment projects, which is putting pressure on current profits [2]. Shareholder Actions - The company's major shareholder, 伊沃斯, has reduced its stake in the company, decreasing its ownership from 29.84% to 27.37% after a series of share reductions totaling 3.12 million shares [3]. - Despite an influx of financing in 2026, the company's financing balance has decreased, falling to 136 million yuan from 144 million yuan, a decline of over 6% [3].

据世界卫生组织等机构介绍，尼帕病毒能攻击人的肺部和大脑，症状包括发烧、头疼、嗜睡、意识模糊 和昏迷，感染者的死亡率可达40%以上。这种病毒从感染到出现症状的潜伏期一般为4天至14天，最长 可达45天。目前尚无专门针对尼帕病毒的疫苗和有效疗法。 据新华社，泰国民航局宣布，1月26日起对来自印度西孟加拉邦的航班进行全面筛查，以防止尼帕病毒 输入泰国。筛查从26日0时起开始实施，同时将根据形势发展随时调整。 编辑丨瑜见 | 代码 | 名称 | 张唱 | 总金额 | 总市值 | 现价 | | --- | --- | --- | --- | --- | --- | | 300463 | 迈克生物 | +20.03% | 7666.6 | 85.86 Z | 14.20 | | 300638 | 凯普生物 | +20.03% | 3.36 Z | 46.87 G | 7.25 | | 688317 | 之江生物 | +20.01% | 3.20 乙 | 49.10 Z | 25.55 | | 301207 | 华兰疫苗 | +20.00% | 5.75 G | 140.3 Z | 23.34 | | 688670 | 金 ...

Core Viewpoint - Eddie Pharmaceuticals is expected to report a net profit loss of approximately 16 million to 24 million yuan for the fiscal year 2025, indicating a year-on-year reduction in loss margin by about 88.67% to 83% while continuing to record losses for five consecutive years [1] Financial Performance - The company has reported net profit losses of 29.99 million yuan, 124 million yuan, 76.07 million yuan, and 141 million yuan from 2021 to 2024 respectively [1] - The projected non-GAAP net loss for 2025 is estimated to be between 17.2 million and 25.2 million yuan, with a year-on-year reduction in loss margin of approximately 88.41% to 83.02% [1] - Expected operating revenue for 2025 is approximately 721 million yuan, representing a year-on-year increase of about 72.57% [1] Revenue Breakdown - Revenue from innovative anti-HIV drugs is anticipated to be 285 million yuan, reflecting a year-on-year increase of 90.34% [1] - Revenue from the subsidiary Nanda Pharmaceuticals is expected to reach 300 million yuan, with a year-on-year increase of 227.38% [1] Corporate Actions - The company plans to invest 130 million yuan to acquire an additional 22.23% stake in Nanda Pharmaceuticals, increasing its ownership from 51.1256% to 73.36% [3] - The acquisition price is based on an evaluation report, with the assessed value of the 22.23% stake being 130 million yuan, which is approximately 92% higher than its book net asset value of 200 million yuan [3] - This acquisition is seen as a strategic move to strengthen control over Nanda Pharmaceuticals and enhance the company's core competitiveness [3][4] Market Performance - As of January 23, the stock price of Eddie Pharmaceuticals rose by 2.59% to 18.64 yuan per share, with a total market capitalization of approximately 7.843 billion yuan [5] - The stock has seen a cumulative increase of about 157% over the past month [5]

证券日报网讯1月25日，艾迪药业发布公告称，公司预计2025年度营业收入约72，101.19万元，同比增 加约72.57%；归属于母公司所有者的净利润约-1，600.00万元到-2，400.00万元，亏损幅度同比下降约 88.67%至83.00%。 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Insights - The report highlights that the pharmaceutical sector is showing resilience, with a focus on capturing opportunities from companies that can deliver on their growth potential. The report suggests that investors should continue to allocate to pharmaceutical bottom assets as fund holdings have returned to a low level [3][10] - The report indicates that the A-share funds' top ten holdings in the pharmaceutical sector account for 9.15%, a decrease of 1.93 percentage points from the previous period. Excluding pharmaceutical funds, the allocation drops to 3.43%, down 1.39 percentage points [3][10] - The report emphasizes the strong performance of certain pharmaceutical companies, particularly in innovative drugs and upstream life sciences, with notable profit growth forecasts for companies like Zhaoyan New Drug and Kangchen Pharmaceutical [3][10] Summary by Sections Market Dynamics - The pharmaceutical sector has outperformed the broader market, with a return of 6.66% compared to the CSI 300's 1.57% since the beginning of 2026, indicating a 5.10 percentage point advantage [14] - Recent performance shows a mixed trend, with pharmaceutical commercial, traditional Chinese medicine, and medical devices showing positive growth, while chemical pharmaceuticals and medical services have declined [10][14] Valuation Metrics - The current valuation of the pharmaceutical sector is at 23.3 times PE based on 2026 earnings forecasts, which is a premium of 11.3% compared to the overall A-share market (excluding financials) at approximately 21.0 times PE [17] - Using the TTM valuation method, the pharmaceutical sector is valued at 30.3 times PE, which is below its historical average of 34.9 times PE, indicating a relative premium of 11.2% over the broader market [17] Recommended Stocks - Key recommended stocks include WuXi Biologics, Sangfor Technologies, Tigermed, and others, with an average increase of 13.41% in January, outperforming the pharmaceutical sector by 6.74 percentage points [26][27] - The report notes that the top ten pharmaceutical stocks held by public funds include companies like Hengrui Medicine and WuXi AppTec, with a strong preference for innovative drugs and leading players in niche markets [3][10]

Investment Rating - The report indicates a cautious outlook on the pharmaceutical sector, with a focus on investment opportunities in the CXO segment and AI pharmaceutical development [2][3]. Core Insights - The pharmaceutical sector's performance has been mixed, with the Shenwan Pharmaceutical and Biological Index declining by 0.4% while the Shanghai Composite Index rose by 0.84% [4][6]. - The report highlights the ongoing transformation in China's pharmaceutical retail industry, emphasizing the shift from traditional drug sales to comprehensive health services, supported by government initiatives [13][14]. - New drug development remains active, with several significant clinical trial applications and promising results from innovative therapies, particularly in oncology and AI-driven drug discovery [15][16][17]. Market Performance - The Shenwan Pharmaceutical and Biological Index ranked 27th among 31 Shenwan first-level sub-industries, with a current overall valuation of 30.3 times earnings, placing it 12th among all first-level industries [4][6]. - Various sub-sectors showed differing performance, with raw materials (+2.4%) and offline pharmacies (+9.7%) performing well, while medical research outsourcing (-4.0%) and chemical preparations (-1.7%) faced declines [6][8]. Recent Key Events - The report notes the significant population dynamics in China, with a total population of approximately 1.40489 billion by the end of 2025, which continues to support economic growth [12]. - The Ministry of Commerce and other departments have issued guidelines to promote high-quality development in the pharmaceutical retail sector, focusing on enhancing service capabilities and optimizing industry structure [13][14]. - Several companies, including BaiLi Tianheng and Moderna, have made strides in drug development, with notable advancements in cancer therapies and AI applications in pharmaceuticals [15][16][17]. Company Dynamics - The report identifies several companies with promising performance forecasts for 2025, including WuXi AppTec, Kanglong Chemical, and Tigermed, highlighting their potential as investment targets [23][26]. - The AI healthcare platform OpenEvidence successfully raised $250 million in Series D funding, reflecting strong growth and increasing adoption among healthcare professionals [23][24].

Core Viewpoint - The company, Aidi Pharmaceutical (688488.SH), is required to pay a total tax amount of approximately 19.95 million yuan as notified by the tax authorities in Yangzhou [1] Group 1: Tax Payment Details - The company will complete the payment of the aforementioned tax within 15 days as per the requirements [1] - The tax payment does not involve any late fees or administrative penalties [1] - The tax amount will be included in the current profit and loss for the fiscal year 2025 [1]

（原标题：艾迪药业(688488.SH)：补缴税款共计约1995.20万元） 格隆汇1月25日丨艾迪药业(688488.SH)公布，根据扬州市税务部门的通知，公司需补缴税款共计约 1,995.20万元。公司将按照要求于15日内将上述税款全部缴纳完毕。本次补缴税款不涉及滞纳金，不涉 及行政处罚，上述税款计入2025年度当期损益。 ...

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a gain of 1.26% on January 23, 2025, outperforming the CSI 300 index by 1.71 percentage points, ranking 10th among 31 sub-industries in the Shenwan classification. Notable performers included offline pharmacies (+6.79%), pharmaceutical distribution (+2.66%), and vaccines (+2.26%), while blood products (+0.58%), medical R&D outsourcing (+0.68%), and in vitro diagnostics (+1.37%) lagged behind [4]. - Takeda's new drug Oveporexton has been proposed for priority review by the National Medical Products Administration (NMPA) in China, aimed at treating narcolepsy type 1 in patients aged 16 and above. The drug has shown positive results in two pivotal Phase 3 studies [5]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceuticals: Neutral [3]